<DOC>
	<DOCNO>NCT03095105</DOCNO>
	<brief_summary>purpose study compare pharmacokinetic profile BIA 6-512 healthy elderly subject versus healthy young subject single repeat oral administration 200 mg BIA 6-512 .</brief_summary>
	<brief_title>Pharmacokinetic Profile BIA 6-512 Healthy Elderly Subjects Versus Healthy Young Subjects</brief_title>
	<detailed_description>Single-centre , open-label study healthy young ( 18-40 year ) elderly ( 65 year old ) subject . The study consist single-dose phase follow repeat dose phase ( 3 time daily , 8-h interval ) . Subjects admit day prior first dose ( Day 1 ) . On day 1 , single dose 200 mg BIA 6-512 ( Dose 1 ) administer morning . On day 2 , repeat dose phase start 24 h post first dose . In repeat dose phase ( Doses 2 8 ) subject receive 200 mg BIA 6-512 every 8 hour morning day 4 ( approximately 72 hour post first dose ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Male female subject age 18 40 year , inclusive ( young ) ; male female subject age 65 year ( elderly ) . Body mass index ( BMI ) 19 30 kg/m2 , inclusive . Healthy determine inter¬view , prestudy medical history , physical examination , vital sign , neurological examination 12lead ECG ; clinical laboratory test result clinically acceptable screen admission . Negative test HBsAg , antiHCVAb , antiHIV1 Ab antiHIV2 Ab screening . Negative screen drug abuse screen admission . Informed consent sign subject . Cooperative available entire study . Abstinence alcohol 48 hour prior admission ( state subject ) . An alcohol breath test perform screen admission clinic negative . Nonsmokers smoke ≤ 10 cigarette equivalent per day . If female , young group : She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence ; negative urine pregnancy test screen admission . Evidence subject 's medical history medical exa¬mina¬tion clinically significant respiratory , hepatic , renal , gastrointesti¬nal , haematological , lymphatic , neurological , car¬diovascu¬lar , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue significant acute chronic abnormality might influence either safety subject ab¬sorption , dis¬tribution , meta¬bolism excretion active agent investigation . History relevant drug food hypersensitivity . Significant infection know inflammatory process screen admission . Acute gastrointestinal symptom time screen admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Regular use medication within four week prior study admission ( selfmedication prescription ) . Single use medication ( include OTC ) expressly permit within two week prior admission stu¬dy . Abuse alcohol ( equiv¬alent 35 g ethanol per day ) . Vegetarians , vegan subject medical dietary restriction . History alcoholism drug abuse . Participation clinical investigation within two month prior screen . Blood donation 250 ml within two month prior screen . Blood donation less 250 ml plasma donation with¬in one month prior screen . Subjects know suspected : comply study directives reliable trustworthy capable understand evaluate information give part formal information policy ( informed consent ) , particular regard risk discomfort would agree expose precarious financial situation longer weigh possible risk participation unpleasantness may involve . If female , young group : pregnant breastfeeding ; childbearing potential use approve effective contraceptive method ( doublebarrier , intrauterine device abstinence ) use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>